FORBES-TATE

Lobbying for SYDNEXIS · Biopharmaceutical company focused on ophthalmic treatments.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $60,000.00 income · posted Apr 19, 2026

Lobbying activity 1

Health Issues

Issues related to ophthalmic treatments.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem